Q1 2020 Avinger Inc Earnings Call
Avinger (AVGR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
23% Year-Over-Year Revenue Growth Total Pantheris Revenue Increases 75% REDWOOD CITY, CA / ACCESSWIRE / May 13, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the ...
REDWOOD CITY, CA / ACCESSWIRE / May 6, 2020 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced that the underwriters of its previously announced underwritten public offering have exercised in full their option to purchase an additional 1,890,000 shares of its common stock at a price of $0.25 per share. The shares were offered pursuant to a registration statement on Form S-1 previously filed with and declared effective by the Securities and Exchange Commission (SEC). A final prospectus relating to the offering was filed with the SEC and is available on the SEC's website at www.sec.gov.
REDWOOD CITY, CA / ACCESSWIRE / January 28, 2020 / Avinger, Inc. (AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $4.5 million before deducting underwriting discounts and commissions and other estimated offering expenses. The proposed offering equates to 6,428,572 shares of the Company's common stock at a price of $0.70 per share. The Company intends to use the net proceeds from this offering to fund working capital, payment of interest on debt and general corporate purposes, which may include research and development of the Company's Lumivascular platform products, preclinical and clinical trials and studies, regulatory submissions, expansion of sales and marketing organizations and efforts, intellectual property protection and enforcement and capital expenditures.
REDWOOD, CA / ACCESSWIRE / February 4, 2020 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), announced today that its Pantheris atherectomy system was featured in a live case transmission at the Leipzig Interventional Course (LINC) 2020, a leading global forum for new methods in the field of vascular medicine held from January 28 through January 31 in Leipzig, Germany. Dr. Arne Schwindt and Dr. Angeliki Argyriou, vascular surgeons from St. Franziskus Hospital in Münster, Germany, performed the live endovascular procedure using Pantheris during a session entitled, "OCT-guided atherectomy of popliteal stent ISR followed by DCB." The patient for the live case presented with claudication and rest pain in the right leg, stemming from blockages within stents placed in a popliteal vein graft.
REDWOOD CITY, CA / ACCESSWIRE / May 20, 2020 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the Company has submitted a 510(k) application to the U.S. Food & Drug Administration (FDA) for pre-marketing clearance of Ocelaris, a next generation chronic total occlusion (CTO) crossing system utilizing Avinger's proprietary image-guided technology platform. Ocelaris is a product line extension of Avinger's Ocelot family of image-guided CTO crossing catheters. Its design elements include an upgrade of the image capture rate to provide high definition, real-time intravascular imaging similar to the company's Pantheris image-guided atherectomy system and a user-controlled deflectable tip designed to assist in steerability within the lumen.
26% Year-Over-Year Fourth Quarter Revenue Growth Total Pantheris Revenue Increases 69% REDWOOD CITY, CA / ACCESSWIRE / March 5, 2020 / Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company ...
REDWOOD CITY, CA / ACCESSWIRE / May 7, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis ...
REDWOOD CITY, CA / ACCESSWIRE / April 15, 2020 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today reported preliminary results for the first quarter ended March 31, 2020. Revenue in the first quarter of 2020 is expected to be approximately $2.25 million, an increase of 22% over the first quarter of 2019, representing the company's third consecutive quarter with greater than 20% year-over-year revenue growth. Avinger launched 11 new Lumivascular sites during the first quarter in high volume areas, such as Arizona, Michigan, and Louisiana, which also contributed to revenue growth for the quarter.
REDWOOD CITY, CA / ACCESSWIRE / January 31, 2020 / Avinger, Inc. (AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD) today announced the closing of an underwritten public offering of 6,428,572 shares of its common stock at a price of $0.70 per share, for total gross proceeds of approximately $4.5 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. The shares were offered pursuant to a registration statement on Form S-1 previously filed with and declared effective by the Securities and Exchange Commission (SEC). A final prospectus relating to the offering was filed with the SEC and is available on the SEC's website at www.sec.gov.
Post-Market Study Intended to Support Commercial Expansion of Small Vessel Image-Guided Atherectomy Device REDWOOD CITY, CA / ACCESSWIRE / January 23, 2020 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage ...
REDWOOD CITY, CA / ACCESSWIRE / February 25, 2020 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that the results of its SCAN clinical study have been published in the peer-reviewed journal BMC Medical Imaging. SCAN is a prospective, non-inferiority, post-market study comparing optical coherence tomography (OCT) with intravascular ultrasound (IVUS) as a diagnostic imaging tool in the peripheral arteries. Study results showed that OCT imaging with Avinger's Pantheris system demonstrated statistical superiority or equivalence to IVUS on all parameters evaluated.
Q4 2019 Avinger Inc Earnings Call
NEW YORK, NY / ACCESSWIRE / March 5, 2020 / Avinger, Inc. (AVGR) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 5, 2020 at 4:30 PM Eastern Time. ...
REDWOOD CITY, CA / ACCESSWIRE / April 27, 2020 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $3.15 million before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. The proposed offering equates to 12.6 million shares of the Company's common stock at a price of $0.25 per share. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes, which may include research and development of the Company's Lumivascular platform products, preclinical and clinical trials and studies, regulatory submissions, expansion of sales and marketing organizations and efforts, intellectual property protection and enforcement and capital expenditures.
REDWOOD CITY, CA / ACCESSWIRE / January 30, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system ...
REDWOOD CITY, CA / ACCESSWIRE / April 30, 2020 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the closing of an underwritten public offering of 12,600,000 shares of its common stock at a price of $0.25 per share, for total gross proceeds of approximately $3.15 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. Additionally, the Company has granted the underwriters a 45-day option to purchase up to 15% additional shares of common stock to cover over-allotments, if any. The shares were offered pursuant to a registration statement on Form S-1 previously filed with and declared effective by the Securities and Exchange Commission (SEC).
REDWOOD CITY, CA / ACCESSWIRE / February 27, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system ...
If you're interested in Avinger, Inc. (NASDAQ:AVGR), then you might want to consider its beta (a measure of share...